Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blow-Fill-Seal Sterile CDMO Business is focusing on complex clinical to commercial-stage formulation and manufacturing. The Business supports a global, blue-chip customer base with a broad array of products that leverage its BFS sterile manufacturing capabilities and formulation competency in complex chemistries including small molecule, biologics, macromolecules, and potent compounds.

Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.

Catalent (CTLT) Surges on Rumors of Acquisition by Danaher

Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Misses Q2 Earnings Estimates

Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

The stock price of Catalent Inc (NYSE: CTLT) surged by 19.54% today. This is why.

CTLT Stock: 19.54% Surge Explanation

Apple

Amazon

Activision Blizzard

Cisco Systems

Alphabet

KB Home

Newmont Mining

PulteGroup

Tesla

Tyson Foods

Take-Two Interactive Software

U.S. stock markets opened the trading week with declines on Monday, Feb. 6, on concerns about additional tightening moves by the Federal Reserve.

Markets Drop for Second-Straight Day on Fed Hike Fears

Celsius Holdings

Even as markets were under pressure, market participants found things to be happy about with these two companies.

These 2 Stocks Are Making a Pop on Monday

Danaher

Life Storage

Newcrest Mining Ltd

Public Storage

Mergers and acquisitions are off to a hot start in February as major gold miners and public storage REITs propose $28 billion in deals. The post Takeover News: February Opens With M&A Bang As Gold Miners, REITs Pitch $28 Billion In Deals appeared first on Investor's Business Daily.

Takeover News: February Opens With M&A Bang As Gold Miners, REITs Pitch $28 Billion In Deals

Catalent (NYSE: CTLT ), which manufactures pharmaceutical products, is soaring more than 20% in early trading today. Over the weekend, Bloomberg reported that Danaher (NYSE: DHR ) is potentially interested in acquiring the company.

Why Is Catalent (NYSE:CTLT) Stock Up 20% Today?

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Catalent (CTLT)

Catalent stock launched higher Monday on a rumor that Danaher could acquire it in a bid to compete with Thermo Fisher Scientific. The post Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover appeared first on Investor's Business Daily.

Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover

After two major healthcare and life sciences deals at the end of 2022, M&A in the industry could be about to rebound.

Catalent Stock Surges on Report of Danaher Interest

Life Sciences Company Danaher Corp. DHR, -0.31% is interested in taking over contract manufacturer Catalent Inc. CTLT, -1.04% and is willing to pay a significant premium for the company, Bloomberg reported Monday, citing people familiar with the matter. It's unclear whether Catalent is receptive, the people said, adding that a deal is not imminent.

Catalent stock rockets 21% premarket on report of takeover interest from Danaher

Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.

Danaher interested in buying life sciences firm Catalent- Bloomberg News

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Align Technology

Generac Holdings

Match Group

PayPal

Signature Bank

SVB Financial Group

V.F.

Remember all the beat-up stocks investors wrote off last year? In an interesting twist, last year's worst stocks are turning into the first.

The Market's 10 Worst Stocks Are Now First

SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America. Mr. Zayas will be responsible for all of the company's North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland. He will serve on the Executive Leadership Team, reporting directly to Catalent's President & Chief Executive Officer, Alessandro Maselli.

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

Avantor Inc.

Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

Investors were net sellers of Catalent equity across the back end of 2022. Much of the downside is explained by diminishing Covid-19 revenues and potential near-term challenges to earnings quality.

Catalent: Starting Valuations, ROIC Supportive, Rate Buy

Sarepta Therapeutics

SOMERSET, N.J. & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). The agreement also structures how Catalent may support multiple gene therapy candidates in Sarepta's pipeline for limb-girdle muscular dystrophy (LGMD).

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 at 5:15 p.m. EST.

Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

This has been the year of reckoning for Big Tech stocks — even those of companies that have continued to grow sales by double digits.

These 20 stocks were the biggest losers of 2022

Caesars Entertainment

DISH Network

Expedia

Warner Bros Discovery Inc

Savvy investors know to stick with stocks in an uptrend. But analysts are still pounding the table for some S&P 500 stocks.

Analysts Pound The Table For 11 Stocks Trading For 50% Off

Global Payments

Phew. The S&P 500's horrible year that was 2022 is finally just about over. And analysts have picked their favorite spots.

News for Catalent Stock (CTLT)